Fujifilm Diosynth Biotechnologies secured a 10-year manufacturing agreement worth over $3 billion with Regeneron Pharmaceuticals to produce the drugmaker’s biologic medicines at its North Carolina facility. The contract will nearly double Regeneron’s US manufacturing capacity as the biotech company expands its commercial portfolio.
Under the agreement, Fujifilm will manufacture Regeneron’s biologics at its new Holly Springs facility, scheduled to begin operations later this year. The deal represents a significant expansion of Fujifilm’s contract manufacturing business, which has become a growing revenue source for the Japanese company as it diversifies beyond its traditional photography roots.
Leonard Schleifer, Regeneron’s CEO, cited the company’s expanding pipeline as driving the need for additional manufacturing capacity. The agreement aligns with Regeneron’s strategy of maintaining significant US-based production while supporting additional capacity for its growing portfolio of approved and experimental treatments.
The partnership is part of Fujifilm’s broader $7 billion expansion of manufacturing facilities across Europe and the United States. Toshihisa Iida, a Fujifilm corporate vice president, noted the company has invested approximately $4 billion in US biopharmaceutical manufacturing sites and plans to create 1,400 new jobs in North Carolina by 2031.
For Regeneron, the deal complements its own manufacturing investments, including a $3.6 billion expansion of its Tarrytown, New York campus that will create about 1,000 high-skill jobs.
